ILOSONE
LOE ApproachingNDAORALSUSPENSION
Approved
Apr 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ILOSONE is an oral suspension small-molecule antibiotic approved in 1967 by Eli Lilly and Company. The specific mechanism of action and indications are not documented in available data, but the formulation and age suggest a macrolide-class antibiotic used for bacterial infections. This legacy product operates in a mature, competitive market with limited differentiation.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating downsizing or transition planning for brand team roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ILOSONE presents limited career development opportunities due to its mature lifecycle and approaching loss of exclusivity. Roles are primarily defensive, focused on maximizing remaining market share and managing transition to generic competition rather than driving innovation or growth.
Brand Manager (Legacy)Sales Representative
Worked on ILOSONE at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.